{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:51:57Z","timestamp":1793296317852,"version":"4.5.0"},"reference-count":170,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001332","name":"Council for Scientific and Industrial Research, South Africa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001332","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","award":["CRG\/2020\/002630"],"award-info":[{"award-number":["CRG\/2020\/002630"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejmech.2025.118264","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T22:31:41Z","timestamp":1760394701000},"page":"118264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"P1","title":["Structural and functional insights into PPAR-\u03b3: Review of its potential and drug design innovations for the development of antidiabetic agents"],"prefix":"10.1016","volume":"302","author":[{"given":"Ojasvi","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tathagata","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1745-9697","authenticated-orcid":false,"given":"Gita","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"32","key":"10.1016\/j.ejmech.2025.118264_bib1","doi-asserted-by":"crossref","first-page":"20230","DOI":"10.1074\/jbc.272.32.20230","article-title":"Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3): differential activity of PPAR\u03b31 and-2 isoforms and influence of insulin","volume":"272","author":"Werman","year":"1997","journal-title":"J. Biol. Chem."},{"issue":"6698","key":"10.1016\/j.ejmech.2025.118264_bib2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/25931","article-title":"Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-\u03b3","volume":"395","author":"Nolte","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118264_bib3","unstructured":"Federation, I.d., Diabetes facts and figures https:\/\/idf.org\/about-diabetes\/diabetes-facts-figures\/. 2025."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118264_bib4","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev.med.53.082901.104018","article-title":"The mechanisms of action of PPARs","volume":"53","author":"Berger","year":"2002","journal-title":"Annu. Rev. Med."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118264_bib5","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1161\/CIRCULATIONAHA.104.475673","article-title":"Peroxisome proliferator\u2013activated receptors as transcriptional nodal points and therapeutic targets","volume":"115","author":"Brown","year":"2007","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ejmech.2025.118264_bib6","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/0092-8674(92)90031-7","article-title":"Control of the peroxisomal \u03b2-oxidation pathway by a novel family of nuclear hormone receptors","volume":"68","author":"Dreyer","year":"1992","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118264_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202301738","article-title":"Recent studies of nitrogen and sulfur containing heterocyclic analogues as novel antidiabetic agents: a review","volume":"21","author":"Gharge","year":"2024","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.ejmech.2025.118264_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.807548","article-title":"Trends in antidiabetic drug discovery: FDA approved drugs, new drugs in clinical trials and global sales","volume":"12","author":"Dahl\u00e9n","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"suppl_1","key":"10.1016\/j.ejmech.2025.118264_bib9","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.2337\/diabetes.53.2007.S43","article-title":"The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity","volume":"53","author":"Ferr\u00e9","year":"2004","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.ejmech.2025.118264_bib10","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.3892\/mmr.2013.1714","article-title":"Role of PPARs in inflammatory processes associated with metabolic syndrome","volume":"8","author":"Fuentes","year":"2013","journal-title":"Mol. Med. Rep."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118264_bib11","article-title":"Peroxisome proliferator\u2010activated receptor targets for the treatment of metabolic diseases","volume":"2013","author":"Monsalve","year":"2013","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.ejmech.2025.118264_bib12","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejmech.2019.01.067","article-title":"Role of PPAR receptor in different diseases and their ligands: physiological importance and clinical implications","volume":"166","author":"Mirza","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118264_bib13","doi-asserted-by":"crossref","first-page":"353","DOI":"10.4274\/tjps.galenos.2021.70105","article-title":"Peroxisome proliferator-activated receptors as superior targets for treating diabetic disease, design strategies-review article","volume":"19","author":"T Qaoud","year":"2022","journal-title":"Turkish Journal of Pharmaceutical Sciences"},{"issue":"3","key":"10.1016\/j.ejmech.2025.118264_bib14","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/MJT.0b013e3181c08081","article-title":"PPAR-\u03b3 agonists and their role in type 2 diabetes mellitus management","volume":"17","author":"Bermudez","year":"2010","journal-title":"Am. J. Therapeut."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118264_bib15","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/cbdd.14020","article-title":"A new insight into the treatment of diabetes by means of pan PPAR agonists","volume":"100","author":"Chandra","year":"2022","journal-title":"Chem. Biol. Drug Des."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118264_bib16","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00005-008-0037-y","article-title":"Structure and physiological functions of the human peroxisome proliferator-activated receptor \u03b3","volume":"56","author":"Zieleniak","year":"2008","journal-title":"Arch. Immunol. Ther. Exp."},{"issue":"2\u20135","key":"10.1016\/j.ejmech.2025.118264_bib17","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jsbmb.2004.12.025","article-title":"Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes","volume":"93","author":"Tan","year":"2005","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"11","key":"10.1016\/j.ejmech.2025.118264_bib18","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/s11745-004-1333-0","article-title":"Mechanisms of regulation of gene expression by fatty acids","volume":"39","author":"Nakamura","year":"2004","journal-title":"Lipids"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118264_bib19","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1089\/15209150260007381","article-title":"Physiological and therapeutic roles of peroxisome proliferator-activated receptors","volume":"4","author":"Berger","year":"2002","journal-title":"Diabetes Technol. Therapeut."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118264_bib20","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1080\/15569543.2019.1673425","article-title":"The effects of PPAR-\u03b3 agonist pioglitazone on anxiety and depression-like behaviors in lipopolysaccharide injected rats","volume":"40","author":"Beheshti","year":"2021","journal-title":"Toxin Rev."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118264_bib21","doi-asserted-by":"crossref","first-page":"728","DOI":"10.3390\/biom14060728","article-title":"New insights into the role of PPAR\u03b3 in skin physiopathology","volume":"14","author":"Briganti","year":"2024","journal-title":"Biomolecules"},{"issue":"15","key":"10.1016\/j.ejmech.2025.118264_bib22","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.3390\/cells11152432","article-title":"Peroxisome proliferator-activated receptors and the hallmarks of cancer","volume":"11","author":"Wagner","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118264_bib23","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.pharmthera.2005.10.009","article-title":"Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance","volume":"111","author":"Guo","year":"2006","journal-title":"Pharmacol. Therapeut."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118264_bib24","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.tem.2007.02.001","article-title":"Transcriptional regulation of the GLUT4 gene: from PPAR-\u03b3 and FOXO1 to FFA and inflammation","volume":"18","author":"Armoni","year":"2007","journal-title":"Trends Endocrinol. Metabol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118264_bib25","doi-asserted-by":"crossref","first-page":"E219","DOI":"10.1152\/ajpendo.00695.2006","article-title":"Suppression of PPAR-\u03b3 attenuates insulin-stimulated glucose uptake by affecting both GLUT1 and GLUT4 in 3T3-L1 adipocytes","volume":"293","author":"Liao","year":"2007","journal-title":"Am. J. Physiol. Endocrinol. Metabol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118264_bib26","doi-asserted-by":"crossref","DOI":"10.1155\/2008\/745804","article-title":"PPAR\u2010\u03b3 in the cardiovascular system","volume":"2008","author":"Duan","year":"2008","journal-title":"PPAR Res."},{"issue":"Suppl 4","key":"10.1016\/j.ejmech.2025.118264_bib27","article-title":"The role of Nrf2 and PPAR\u03b3 in the improvement of oxidative stress in hypertension and cardiovascular diseases","volume":"69","author":"Dovinova","year":"2020","journal-title":"Physiol. Res."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118264_bib28","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.3390\/ijms24032345","article-title":"Pharmacological utility of PPAR modulation for angiogenesis in cardiovascular disease","volume":"24","author":"Wagner","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118264_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.826811","article-title":"The role of peroxisome proliferator-activated receptor gamma and atherosclerosis: post-translational modification and selective modulators","volume":"13","author":"Yin","year":"2022","journal-title":"Front. Physiol."},{"issue":"19","key":"10.1016\/j.ejmech.2025.118264_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910573","article-title":"The PPAR\u03b1 and PPAR\u03b3 epigenetic landscape in cancer and immune and metabolic disorders","volume":"22","author":"Porcuna","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118264_bib31","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2174\/1568009619666191209102015","article-title":"PPAR\u03b3 agonists in combination cancer therapies","volume":"20","author":"Mrowka","year":"2020","journal-title":"Curr. Cancer Drug Targets"},{"issue":"13","key":"10.1016\/j.ejmech.2025.118264_bib32","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.7150\/jca.42663","article-title":"The role and function of PPAR\u03b3 in bladder cancer","volume":"11","author":"Peng","year":"2020","journal-title":"J. Cancer"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118264_bib33","doi-asserted-by":"crossref","first-page":"805","DOI":"10.3390\/ijms22020805","article-title":"PPAR gamma: from definition to molecular targets and therapy of lung diseases","volume":"22","author":"Carvalho","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"16","key":"10.1016\/j.ejmech.2025.118264_bib34","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.2174\/0929867327666200716113136","article-title":"Role of peroxisome proliferator-activated receptor gamma (PPAR\u03b3) in different disease states: recent updates","volume":"28","author":"Mal","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118264_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174562","article-title":"PPAR-gamma agonists: potential modulators of autophagy in obesity","volume":"912","author":"Faghfouri","year":"2021","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118264_bib36","article-title":"PPAR\u03b3 and its agonists in chronic kidney disease","volume":"2020","author":"Ma","year":"2020","journal-title":"International Journal of Nephrology"},{"key":"10.1016\/j.ejmech.2025.118264_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11882-021-01022-x","article-title":"The role of PPAR-\u03b3 in allergic disease","volume":"21","author":"Stark","year":"2021","journal-title":"Curr. Allergy Asthma Rep."},{"key":"10.1016\/j.ejmech.2025.118264_bib38","article-title":"Minutes of PPAR-\u03b3 agonism and neuroprotection","volume":"140","author":"Kumar","year":"2020","journal-title":"Neurochem. Int."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118264_bib39","doi-asserted-by":"crossref","first-page":"985","DOI":"10.3390\/ijms22030985","article-title":"Inflammatory bowel disease: new insights into the interplay between environmental factors and PPAR\u03b3","volume":"22","author":"Caioni","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118264_bib40","doi-asserted-by":"crossref","DOI":"10.1155\/2009\/818945","article-title":"Cross\u2010talk between PPAR\u03b3 and insulin signaling and modulation of insulin sensitivity","volume":"2009","author":"Leonardini","year":"2009","journal-title":"PPAR Res."},{"key":"10.1016\/j.ejmech.2025.118264_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.624112","article-title":"PPARgamma in metabolism, immunity, and cancer: unified and diverse mechanisms of action","volume":"12","author":"Hernandez-Quiles","year":"2021","journal-title":"Front. Endocrinol."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118264_bib42","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.beem.2007.09.004","article-title":"PPAR agonists: multimodal drugs for the treatment of type-2 diabetes","volume":"21","author":"Gross","year":"2007","journal-title":"Best Pract. Res. Clin. Endocrinol. Metabol."},{"key":"10.1016\/j.ejmech.2025.118264_bib43","series-title":"Role of Peroxisome proliferator-activated Receptor gamma2 (PPAR-\u03b3g2) Gene Polymorphism in Type 2 Diabetes Mellitus","author":"Sokkar","year":"2010"},{"key":"10.1016\/j.ejmech.2025.118264_bib44","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/9781119785033.ch12","article-title":"Glitazones and glitazars","author":"Fisher","year":"2022","journal-title":"Diabetes Drug Notes"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118264_bib45","article-title":"Etiology of drug-induced edema: a review of dihydropyridine, thiazolidinedione, and other medications causing edema","volume":"16","author":"Sinnathamby","year":"2024","journal-title":"Cureus"},{"issue":"8","key":"10.1016\/j.ejmech.2025.118264_bib46","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1358\/mf.2002.24.8.705072","article-title":"Experimental approaches to study PPAR gamma agonists as antidiabetic drugs","volume":"24","author":"Vazquez","year":"2002","journal-title":"Methods Find. Exp. Clin. Pharmacol."},{"issue":"10","key":"10.1016\/j.ejmech.2025.118264_bib47","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/medicina58101475","article-title":"An update on the current and emerging use of thiazolidinediones for type 2 diabetes","volume":"58","author":"Giglio","year":"2022","journal-title":"Medicina"},{"issue":"9","key":"10.1016\/j.ejmech.2025.118264_bib48","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1021\/jm101360s","article-title":"Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators","volume":"55","author":"Pirat","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118264_bib49","series-title":"Diabetes Mellitus","first-page":"43","article-title":"PPAR\u03b3 (peroxisome proliferator-activated receptor gamma) receptor in diabetes mellitus","author":"Sood","year":"2025"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118264_bib50","article-title":"New insights into the PPAR\u03b3 agonists for the treatment of diabetic nephropathy","volume":"2014","author":"Jia","year":"2014","journal-title":"PPAR Res."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118264_bib51","doi-asserted-by":"crossref","DOI":"10.1155\/2008\/936906","article-title":"The development of INT131 as a selective PPAR\u03b3 modulator: approach to a safer insulin sensitizer","volume":"2008","author":"Higgins","year":"2008","journal-title":"PPAR Res."},{"key":"10.1016\/j.ejmech.2025.118264_bib52","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3389\/fphar.2017.00317","article-title":"Selective tissue distribution mediates tissue-dependent PPAR\u03b3 activation and insulin sensitization by INT131, a selective PPAR\u03b3 modulator","volume":"8","author":"Xie","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118264_bib53","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1517\/13543781003640169","article-title":"Discovery and development of selective PPAR\u03b3 modulators as safe and effective antidiabetic agents","volume":"19","author":"Doshi","year":"2010","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2025.118264_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113542","article-title":"Design, synthesis, and biological evaluation of novel sulindac derivatives as partial agonists of PPAR\u03b3 with potential anti-diabetic efficacy","volume":"222","author":"Huang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118264_bib55","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2165\/00003495-200060020-00009","article-title":"Pioglitazone","volume":"60","author":"Gillies","year":"2000","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118264_bib56","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1517\/14740331003623218","article-title":"Pioglitazone: side effect and safety profile","volume":"9","author":"Shah","year":"2010","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.ejmech.2025.118264_bib57","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00003495-200666010-00005","article-title":"Pioglitazone: a review of its use in type 2 diabetes mellitus","volume":"66","author":"Waugh","year":"2006","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.ejmech.2025.118264_bib58","article-title":"Pioglitazone for type 2 diabetes mellitus","author":"Richter","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejmech.2025.118264_bib59","unstructured":"ClinicalTrials.gov. 06-09-2025]; Available from: https:\/\/clinicaltrials.gov\/."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118264_bib60","article-title":"Rosiglitazone for type 2 diabetes mellitus","author":"Richter","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejmech.2025.118264_bib61","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2165\/00003495-199957060-00007","article-title":"Rosiglitazone","volume":"57","author":"Balfour","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118264_bib62","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.2165\/00003495-200262120-00007","article-title":"Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus","volume":"62","author":"Wagstaff","year":"2002","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.ejmech.2025.118264_bib63","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1592\/phco.21.13.1082.34615","article-title":"A review of rosiglitazone in type 2 diabetes mellitus","volume":"21","author":"Werner","year":"2001","journal-title":"Pharmacotherapy"},{"issue":"9681","key":"10.1016\/j.ejmech.2025.118264_bib64","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","article-title":"Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial","volume":"373","author":"Home","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2025.118264_bib65","unstructured":"More, J.D., et al.,The Review Article on\u2013Analytical Method Development and Validation of Oral Anti-diabetics Pharmaceutical Dosage Form Based on Recent Literature."},{"key":"10.1016\/j.ejmech.2025.118264_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1514120","article-title":"Revolutionizing ovarian cancer therapy by drug repositioning for accelerated and cost-effective treatments","volume":"14","author":"Villegas-Vazquez","year":"2025","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118264_bib67","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/ann.34.3.217.224","article-title":"Glitazones: clinical effects and molecular mechanisms","volume":"34","author":"Stumvoll","year":"2002","journal-title":"Ann. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118264_bib68","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/00003495-199754010-00010","article-title":"Troglitazone","volume":"54","author":"Spencer","year":"1997","journal-title":"Drugs"},{"issue":"24","key":"10.1016\/j.ejmech.2025.118264_bib69","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118264_bib70","series-title":"Troglitazone. Adverse Drug Reactions","first-page":"419","author":"Yokoi","year":"2009"},{"issue":"4","key":"10.1016\/j.ejmech.2025.118264_bib71","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0002-9343(02)01529-2","article-title":"Troglitazone-induced liver failure: a case study","volume":"114","author":"Graham","year":"2003","journal-title":"Am. J. Med."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118264_bib72","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.phrs.2007.03.002","article-title":"PPAR dual agonists: are they opening Pandora's box?","volume":"56","author":"Balakumar","year":"2007","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2025.118264_bib73","series-title":"Diabetes-Perspectives in Drug Therapy","author":"Schwanstecher","year":"2011"},{"issue":"10","key":"10.1016\/j.ejmech.2025.118264_bib74","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1358\/dof.2006.031.10.1034583","article-title":"Advances in antidiabetic agents targeting peroxisome proliferator-activated receptors (PPARs)","volume":"31","author":"Cheng","year":"2006","journal-title":"Drugs Future"},{"issue":"5","key":"10.1016\/j.ejmech.2025.118264_bib75","first-page":"1644","article-title":"Recent advances on novel dual-acting peroxisome proliferator-activated receptor alpha and gamma agonists","volume":"4","author":"Toma","year":"2013","journal-title":"Int. J. Pharmaceut. Sci. Res."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118264_bib76","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/FJC.0000000000000891","article-title":"The glitazars paradox: cardiotoxicity of the metabolically beneficial dual PPAR\u03b1 and PPAR\u03b3 activation","volume":"76","author":"Kalliora","year":"2020","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118264_bib77","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1517\/14656566.2015.1009894","article-title":"Saroglitazar for the treatment of dyslipidemia in diabetic patients","volume":"16","author":"Joshi","year":"2015","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2025.118264_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-020-01073-w","article-title":"Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study)","volume":"19","author":"Krishnappa","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ejmech.2025.118264_bib79","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2147\/DMSO.S49592","article-title":"Saroglitazar for the treatment of hypertrig-lyceridemia in patients with type 2 diabetes: current evidence","author":"Sosale","year":"2015","journal-title":"Diabetes, Metab. Syndrome Obes. Targets Ther."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118264_bib80","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2174\/13894501113149990199","article-title":"The first approved agent in the Glitazar's class: saroglitazar","volume":"15","author":"Agrawal","year":"2014","journal-title":"Curr. Drug Targets"},{"issue":"5","key":"10.1016\/j.ejmech.2025.118264_bib81","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.2337\/dc05-1146","volume":"29","author":"Kendall","year":"2006","journal-title":"Diabetes Care"},{"issue":"20","key":"10.1016\/j.ejmech.2025.118264_bib82","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1001\/jama.294.20.joc50147","article-title":"Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus","volume":"294","author":"Nissen","year":"2005","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.ejmech.2025.118264_bib83","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1463-1326.2011.01429.x","article-title":"Metabolic effects of muraglitazar in type 2 diabetic subjects","volume":"13","author":"Fernandez","year":"2011","journal-title":"Diabetes Obes. Metabol."},{"issue":"8","key":"10.1016\/j.ejmech.2025.118264_bib84","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.clinthera.2005.08.005","article-title":"Muraglitazar, a dual (\u03b1\/\u03b3) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes","volume":"27","author":"Buse","year":"2005","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejmech.2025.118264_bib85","unstructured":"Squibb, B.-M., PPAR - Combination with Metformin. National Library of Medicine."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118264_bib86","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40265-021-01648-1","article-title":"Chiglitazar: first approval","volume":"82","author":"Deeks","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118264_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104318","article-title":"Drugs targeting peroxisome proliferator-activated receptors","author":"Xie","year":"2025","journal-title":"Drug Discov. Today"},{"issue":"15","key":"10.1016\/j.ejmech.2025.118264_bib88","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.scib.2021.02.027","article-title":"Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS)","volume":"66","author":"Jia","year":"2021","journal-title":"Sci. Bull."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118264_bib89","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3803\/EnM.2021.1155","article-title":"Lobeglitazone, A peroxisome proliferator-activated receptor-gamma agonist, inhibits papillary thyroid cancer cell migration and invasion by suppressing p38 MAPK signaling pathway","volume":"36","author":"Jin","year":"2021","journal-title":"Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118264_bib90","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.phymed.2013.08.020","article-title":"Combination therapy: a new strategy to manage diabetes and its complications","volume":"21","author":"Prabhakar","year":"2014","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ejmech.2025.118264_bib91","series-title":"Nonalcoholic Fatty Liver Disease: Updates on Associations with the Metabolic Syndrome and Lipid Profile and Effects of Treatment with PPAR-\u03b3 Agonists","first-page":"64","author":"Polyzos","year":"2017"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118264_bib92","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2036.2011.04912.x","article-title":"Meta\u2010analysis: pioglitazone improves liver histology and fibrosis in patients with non\u2010alcoholic steatohepatitis","volume":"35","author":"Boettcher","year":"2012","journal-title":"Aliment Pharmacol. Therapeut."},{"key":"10.1016\/j.ejmech.2025.118264_bib93","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.biopha.2018.12.130","article-title":"Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis\u2013effects of a peroxisome proliferator-activated receptor gamma (PPAR-\u03b3) agonist and a glucagon-like peptide-1 analogue","volume":"111","author":"Daniels","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118264_bib94","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S2468-1253(21)00261-2","article-title":"Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review","volume":"7","author":"Mantovani","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118264_bib95","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12933-023-01798-4","article-title":"Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)","volume":"22","author":"Gourdy","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"issue":"12","key":"10.1016\/j.ejmech.2025.118264_bib96","doi-asserted-by":"crossref","first-page":"bqab157","DOI":"10.1210\/endocr\/bqab157","article-title":"SGLT2 inhibition for cardiovascular diseases, chronic kidney disease, and NAFLD","volume":"162","author":"Ala","year":"2021","journal-title":"Endocrinology"},{"issue":"10","key":"10.1016\/j.ejmech.2025.118264_bib97","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S2468-1253(24)00188-2","article-title":"Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions","volume":"9","author":"Jalleh","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118264_bib98","first-page":"104","article-title":"Current approaches in healing of wounds in diabetes and diabetic foot ulcers","volume":"19","author":"Chauhan","year":"2023","journal-title":"Curr. Bioact. Compd."},{"issue":"30","key":"10.1016\/j.ejmech.2025.118264_bib99","doi-asserted-by":"crossref","first-page":"11091","DOI":"10.1080\/10408398.2023.2232868","article-title":"Treatment of diabetic complications: do flavonoids holds the keys?","volume":"64","author":"Chalotra","year":"2024","journal-title":"Crit. Rev. Food Sci. Nutr."},{"issue":"7","key":"10.1016\/j.ejmech.2025.118264_bib100","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.2337\/diabetes.54.7.2206","article-title":"Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients","volume":"54","author":"Pistrosch","year":"2005","journal-title":"Diabetes"},{"issue":"9","key":"10.1016\/j.ejmech.2025.118264_bib101","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1007\/s00125-009-1423-7","article-title":"Rosiglitazone enhances glucose uptake in glomerular podocytes using the glucose transporter GLUT1","volume":"52","author":"Lennon","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejmech.2025.118264_bib102","doi-asserted-by":"crossref","DOI":"10.1002\/open.202500087","article-title":"Computational approaches for PPAR\u03b3 inhibitor development: recent advances and perspectives","author":"Magwenyane","year":"2025","journal-title":"ChemistryOpen"},{"key":"10.1016\/j.ejmech.2025.118264_bib103","doi-asserted-by":"crossref","DOI":"10.1177\/25424823251359579","article-title":"Association between genetically proxied PPARG activation and early onset alzheimer's disease: a drug target Mendelian randomization study","volume":"9","author":"Zhang","year":"2025","journal-title":"Journal of Alzheimer's Disease Reports"},{"issue":"9","key":"10.1016\/j.ejmech.2025.118264_bib104","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1007\/s00125-010-1787-8","article-title":"Autonomic neuropathy predisposes to rosiglitazone-induced vascular leakage in insulin-treated patients with type 2 diabetes: a randomised, controlled trial on thiazolidinedione-induced vascular leakage","volume":"53","author":"Rennings","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejmech.2025.118264_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104506","article-title":"Peroxisome proliferator-activated receptor \u0263 agonist mediated inhibition of heparanase expression reduces proteinuria","volume":"90","author":"Garsen","year":"2023","journal-title":"EBioMedicine"},{"issue":"5","key":"10.1016\/j.ejmech.2025.118264_bib106","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.lfs.2003.03.004","article-title":"Effect of the new thiazolidinedione-pioglitazone on the development of oxidative stress in liver and kidney of diabetic rabbits","volume":"74","author":"Gumieniczek","year":"2003","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2025.118264_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108907","article-title":"The PPAR\u03b3 agonist pioglitazone produces a female-predominant inhibition of hyperalgesia associated with surgical incision, peripheral nerve injury, and painful diabetic neuropathy","volume":"205","author":"Santos","year":"2022","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.ejmech.2025.118264_bib108","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jpain.2015.11.006","article-title":"Pioglitazone inhibits the development of hyperalgesia and sensitization of spinal nociresponsive neurons in type 2 diabetes","volume":"17","author":"Griggs","year":"2016","journal-title":"J. Pain"},{"key":"10.1016\/j.ejmech.2025.118264_bib109","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.neuropharm.2013.01.020","article-title":"PPAR\u03b3 activation blocks development and reduces established neuropathic pain in rats","volume":"70","author":"Morgenweck","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2025.118264_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117557","article-title":"Neuroprotective effects of ranolazine versus pioglitazone in experimental diabetic neuropathy: targeting Nav1. 7 channels and PPAR-\u03b3","volume":"250","author":"Elkholy","year":"2020","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118264_bib111","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12933-021-01294-7","article-title":"Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug","volume":"20","author":"Nesti","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"issue":"42","key":"10.1016\/j.ejmech.2025.118264_bib112","doi-asserted-by":"crossref","first-page":"33142","DOI":"10.1074\/jbc.M002319200","article-title":"Suppression of rat thromboxane synthase gene transcription by peroxisome proliferator-activated receptor \u03b3 in macrophages via an interaction with NRF2","volume":"275","author":"Ikeda","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2025.118264_bib113","doi-asserted-by":"crossref","first-page":"9676","DOI":"10.1074\/jbc.M104560200","article-title":"Transcription suppression of thromboxane receptor gene by peroxisome proliferator-activated receptor-\u03b3 via an interaction with Sp1 in vascular smooth muscle cells","volume":"277","author":"Sugawara","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"Suppl 3","key":"10.1016\/j.ejmech.2025.118264_bib114","doi-asserted-by":"crossref","first-page":"S343","DOI":"10.33549\/physiolres.933439","article-title":"The role of PPARgamma in cardiovascular diseases","volume":"65","author":"Kvandov\u00e1","year":"2016","journal-title":"Physiol. Res."},{"issue":"6764","key":"10.1016\/j.ejmech.2025.118264_bib115","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/47254","article-title":"Dominant negative mutations in human PPAR\u03b3 associated with severe insulin resistance, diabetes mellitus and hypertension","volume":"402","author":"Barroso","year":"1999","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.ejmech.2025.118264_bib116","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1056\/NEJM199810013391403","article-title":"Obesity associated with a mutation in a genetic regulator of adipocyte differentiation","volume":"339","author":"Ristow","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118264_bib117","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/sj.ijo.0801191","article-title":"The Pro115Gln and Pro12Ala PPAR gamma gene mutations in obesity and type 2 diabetes","volume":"24","author":"Clement","year":"2000","journal-title":"Int. J. Obes."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118264_bib118","doi-asserted-by":"crossref","first-page":"910","DOI":"10.2337\/diabetes.52.4.910","article-title":"Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-\u03b3","volume":"52","author":"Savage","year":"2003","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.ejmech.2025.118264_bib119","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/3099","article-title":"A Pro12Ala substitution in PPAR\u03b32 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity","volume":"20","author":"Deeb","year":"1998","journal-title":"Nat. Genet."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118264_bib120","doi-asserted-by":"crossref","first-page":"687","DOI":"10.2174\/138161282005140214161949","article-title":"Structure-based drug design to overcome drug resistance: challenges and opportunities","volume":"20","author":"S Ferreira","year":"2014","journal-title":"Curr. Pharm. Des."},{"issue":"20","key":"10.1016\/j.ejmech.2025.118264_bib121","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.3390\/molecules29204881","article-title":"Identification of novel PPAR\u03b3 partial agonists based on virtual screening strategy: in silico and in vitro experimental validation","volume":"29","author":"Lian","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118264_bib122","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2025.1579445","article-title":"Discovery of a novel binding pocket in PPAR\u03b3 for partial agonists: structure-based virtual screening identifies ginsenoside Rg5 as a partial agonist promoting beige adipogenesis","volume":"13","author":"Wang","year":"2025","journal-title":"Front. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2025.118264_bib123","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.2174\/1389450120666190527115538","article-title":"PPAR\u03b3: potential therapeutic target for ailments beyond diabetes and its natural agonism","volume":"20","author":"Shafi","year":"2019","journal-title":"Curr. Drug Targets"},{"issue":"23","key":"10.1016\/j.ejmech.2025.118264_bib124","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.2174\/1381612825666190716094852","article-title":"The journey of thiazolidinediones as modulators of PPARs for the management of diabetes: a current perspective","volume":"25","author":"Ahsan","year":"2019","journal-title":"Curr. Pharm. Des."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118264_bib125","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.bcp.2014.07.018","article-title":"Natural product agonists of peroxisome proliferator-activated receptor gamma (PPAR\u03b3): a review","volume":"92","author":"Wang","year":"2014","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118264_bib126","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1747-0285.2007.00606.x","article-title":"Novel PPAR\u2010gamma agonists identified from a natural product library: a virtual screening, induced\u2010fit docking and biological assay study","volume":"71","author":"Salam","year":"2008","journal-title":"Chem. Biol. Drug Des."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118264_bib127","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2174\/1874104501913010007","article-title":"Inhibition of ppar\u03b3 by natural compounds as a promising strategy in obesity and diabetes","volume":"13","author":"Ammazzalorso","year":"2019","journal-title":"Open Med. Chem. J."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118264_bib128","article-title":"Treatment of obesity\u2010related complications with novel classes of naturally occurring PPAR agonists","volume":"2011","author":"Bassaganya-Riera","year":"2011","journal-title":"Journal of Obesity"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118264_bib129","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3390\/nu15010037","article-title":"Tea plant (Camellia sinensis): a current update on use in diabetes, obesity, and cardiovascular disease","volume":"15","author":"Brimson","year":"2022","journal-title":"Nutrients"},{"issue":"29","key":"10.1016\/j.ejmech.2025.118264_bib130","doi-asserted-by":"crossref","first-page":"11080","DOI":"10.1021\/acs.jafc.3c01669","article-title":"Structurally diverse phenolic amides from the fruits of Lycium barbarum with potent \u03b1-glucosidase, dipeptidyl peptidase-4 inhibitory, and PPAR-\u03b3 agonistic activities","volume":"71","author":"Chen","year":"2023","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.ejmech.2025.118264_bib131","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2147\/JIR.S297348","article-title":"Therapeutic potentials of colocasia affinis leaf extract for the alleviation of streptozotocin-induced diabetes and diabetic complications: in vivo and in silico-based studies","author":"Shill","year":"2021","journal-title":"J. Inflamm. Res."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118264_bib132","doi-asserted-by":"crossref","first-page":"78","DOI":"10.51511\/pr.78","article-title":"Exploring the anti-diabetic potential of stevia-derived compounds through PPAR-\u03b3 targeted molecular docking","volume":"3","author":"Putri","year":"2023","journal-title":"Pharmacy Reports"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118264_bib133","doi-asserted-by":"crossref","first-page":"20","DOI":"10.31788\/RJC.2022.1516646","article-title":"Molecular docking of \u03b2-Sitosterol and stigmasterol isolated from Morinda citrifolia with \u03b1-amylase, \u03b1-glucosidase, dipeptidylpeptidase-IV, and peroxisome proliferator-activated receptor-\u03b3","volume":"15","author":"Lolok","year":"2022","journal-title":"Rasayan J. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118264_bib134","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s13596-021-00598-z","article-title":"Phytochemicals from Nigerian medicinal plants modulate therapeutically-relevant diabetes targets: insight from computational direction","volume":"22","author":"Olawale","year":"2022","journal-title":"Advances in Traditional Medicine"},{"issue":"6","key":"10.1016\/j.ejmech.2025.118264_bib135","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1007\/s00125-016-3912-9","article-title":"Bavachinin, as a novel natural pan-PPAR agonist, exhibits unique synergistic effects with synthetic PPAR-\u03b3 and PPAR-\u03b1 agonists on carbohydrate and lipid metabolism in db\/db and diet-induced obese mice","volume":"59","author":"Feng","year":"2016","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.ejmech.2025.118264_bib136","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s00125-013-2920-2","article-title":"Amorfrutin B is an efficient natural peroxisome proliferator-activated receptor gamma (PPAR\u03b3) agonist with potent glucose-lowering properties","volume":"56","author":"Weidner","year":"2013","journal-title":"Diabetologia"},{"issue":"12","key":"10.1016\/j.ejmech.2025.118264_bib137","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1080\/14786419.2024.2334323","article-title":"PPAR gamma agonistic activity of dillapiole: protective effects against diabetic nephropathy","volume":"39","author":"Shafi","year":"2025","journal-title":"Nat. Prod. Res."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118264_bib138","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.bbagen.2019.01.002","article-title":"Identification and characterization of phytocannabinoids as novel dual PPAR\u03b1\/\u03b3 agonists by a computational and in vitro experimental approach","volume":"1863","author":"D'Aniello","year":"2019","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118264_bib139","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1055\/a-0824-1316","article-title":"Triterpenoids from Hibiscus sabdariffa L. with PPAR\u03b4\/\u03b3 dual agonist action: in Vivo, in vitro and in silico studies","volume":"85","author":"Giacoman-Mart\u00ednez","year":"2019","journal-title":"Planta Med."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118264_bib140","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s13205-021-02811-x","article-title":"Retracted article: ameliorative potential of Operculina turpethum against streptozotocin-induced diabetes in rats: biochemical and histopathological studies","volume":"11","author":"Choudhary","year":"2021","journal-title":"3 Biotech"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118264_bib141","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jep.2014.05.055","article-title":"The use of plants in the traditional management of diabetes in Nigeria: pharmacological and toxicological considerations","volume":"155","author":"Ezuruike","year":"2014","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.ejmech.2025.118264_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2019.152906","article-title":"Antidiabetic potential of gallic acid from Emblica officinalis: improved glucose transporters and insulin sensitivity through PPAR-\u03b3 and Akt signaling","volume":"73","author":"Variya","year":"2020","journal-title":"Phytomedicine"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118264_bib143","doi-asserted-by":"crossref","first-page":"208","DOI":"10.5614\/crbb.2022.3.2\/82KYTCPW","article-title":"Molecular docking-based virtual screening of antidiabetic agents from Songga (Strychnos lucida R. Br.): an Indonesian native plant","volume":"3","author":"Setiawansyah","year":"2022","journal-title":"Current Research on Biosciences and Biotechnology"},{"issue":"9","key":"10.1016\/j.ejmech.2025.118264_bib144","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.3390\/molecules26092682","article-title":"Natural compound 3\u03b2, 7\u03b2, 25-trihydroxycucurbita-5, 23 (E)-dien-19-al from Momordica charantia acts as PPAR\u03b3 ligand","volume":"26","author":"Noruddin","year":"2021","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118264_bib145","article-title":"Identification of antidiabetic inhibitors from Allophylus villosus and Mycetia sinensis by targeting \u03b1-glucosidase and PPAR-\u03b3: in-Vitro, in-vivo, and computational evidence","volume":"32","author":"Azam","year":"2024","journal-title":"Saudi Pharm. J."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118264_bib146","doi-asserted-by":"crossref","DOI":"10.1177\/1559325819862449","article-title":"Ameliorative effect of berberine on neonatally induced type 2 diabetic neuropathy via modulation of BDNF, IGF-1, PPAR-\u03b3, and AMPK expressions","volume":"17","author":"Zhou","year":"2019","journal-title":"Dose Response"},{"issue":"19","key":"10.1016\/j.ejmech.2025.118264_bib147","doi-asserted-by":"crossref","first-page":"6763","DOI":"10.3390\/molecules27196763","article-title":"Thiazolidin-2, 4-dione scaffold: an insight into recent advances as antimicrobial, antioxidant, and hypoglycemic agents","volume":"27","author":"Kumar","year":"2022","journal-title":"Molecules"},{"issue":"19","key":"10.1016\/j.ejmech.2025.118264_bib148","doi-asserted-by":"crossref","DOI":"10.1002\/ejoc.202300184","article-title":"Chemistry and applications of functionalized 2, 4\u2010thiazolidinediones","volume":"26","author":"Ibrahim","year":"2023","journal-title":"Eur. J. Org Chem."},{"issue":"18","key":"10.1016\/j.ejmech.2025.118264_bib149","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.2174\/1389557519666190513093618","article-title":"Chemical synthesis, mechanism of action and anticancer potential of medicinally important thiazolidin-2, 4-dione derivatives: a review","volume":"19","author":"Kumar","year":"2019","journal-title":"Mini Rev. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2025.118264_bib150","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/cmdc.202100177","article-title":"Thiazolidinediones: an in\u2013depth study of their synthesis and application to medicinal chemistry in the treatment of diabetes mellitus","volume":"16","author":"Long","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.118264_bib151","author":"Srinivasa","year":"2023","journal-title":"Novel Thiazolidinedione Derivatives as effective agonists of Peroxisome Proliferator Activator Receptor-\u03b3: A Comprehensive Study on Design, Synthesis, Molecular Docking, MD Simulations, and Antidiabetic Efficacy"},{"key":"10.1016\/j.ejmech.2025.118264_bib152","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s11224-020-01500-4","article-title":"De-novo design and synthesis of conformationally restricted thiazolidine-2, 4-dione analogues: highly selective PPAR-\u03b3 agonist in search of anti-diabetic agent","volume":"31","author":"Chhajed","year":"2020","journal-title":"Struct. Chem."},{"key":"10.1016\/j.ejmech.2025.118264_bib153","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmcr.2024.100151","article-title":"Design, synthesis of new 2, 4-thiazolidinediones: In-silico, in-vivo anti-diabetic and anti-inflammatory evaluation","volume":"11","author":"Gharge","year":"2024","journal-title":"European Journal of Medicinal Chemistry Reports"},{"key":"10.1016\/j.ejmech.2025.118264_bib154","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105342","article-title":"Design, synthesis and bioactivity evaluation of thiazolidinedione derivatives as partial agonists targeting PPAR\u03b3","volume":"116","author":"Sun","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118264_bib155","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2025.141324","article-title":"Design, synthesis, and antidiabetic evaluation of thiazolidinedione derivatives as potent PPAR-\u03b3 agonists: insights from molecular docking, MD simulations and invitro studies","volume":"1328","author":"Srinivasa","year":"2025","journal-title":"J. Mol. Struct."},{"issue":"11","key":"10.1016\/j.ejmech.2025.118264_bib156","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1039\/D3MD00273J","article-title":"Development of novel thiazolidine-2, 4-dione derivatives as PPAR-\u03b3 agonists through design, synthesis, computational docking, MD simulation, and comprehensive in vitro and in vivo evaluation","volume":"14","author":"Srinivasa","year":"2023","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118264_bib157","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115826","article-title":"Integrated fragment-based drug design and virtual screening techniques for exploring the antidiabetic potential of thiazolidine-2, 4-diones: design, synthesis and in vivo studies","volume":"261","author":"Gupta","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118264_bib158","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.bioorg.2018.09.034","article-title":"Design, synthesis, modeling studies and biological evaluation of thiazolidine derivatives containing pyrazole core as potential anti-diabetic PPAR-\u03b3 agonists and anti-inflammatory COX-2 selective inhibitors","volume":"82","author":"Abdellatif","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118264_bib159","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2023.135503","article-title":"Computational studies, synthesis, in-vitro binding and transcription analysis of novel imidazolidine-2, 4-dione and 2-thioxo thiazolidine-4-one based glitazones for central PPAR-\u03b3 agonism","volume":"1285","author":"Kumar","year":"2023","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.ejmech.2025.118264_bib160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116279","article-title":"Novel thiazolidin-4-one benzenesulfonamide hybrids as PPAR\u03b3 agonists: design, synthesis and in vivo anti-diabetic evaluation","volume":"269","author":"Ali","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118264_bib161","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.bioorg.2018.10.025","article-title":"Novel hybrids of benzothiazole-1, 3, 4-oxadiazole-4-thiazolidinone: synthesis, in silico ADME study, molecular docking and in vivo anti-diabetic assessment","volume":"83","author":"Bhutani","year":"2019","journal-title":"Bioorg. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118264_bib162","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1021\/acsomega.3c07149","article-title":"Novel thiazolidinedione and rhodanine derivatives regulate glucose metabolism, improve insulin sensitivity, and activate the peroxisome proliferator-activated \u03b3 receptor","volume":"9","author":"Al Neyadi","year":"2024","journal-title":"ACS Omega"},{"issue":"22","key":"10.1016\/j.ejmech.2025.118264_bib163","doi-asserted-by":"crossref","first-page":"15691","DOI":"10.1039\/D4RA02143F","article-title":"Innovation of 6-sulfonamide-2 H-chromene derivatives as antidiabetic agents targeting \u03b1-amylase, \u03b1-glycosidase, and PPAR-\u03b3 inhibitors with in silico molecular docking simulation","volume":"14","author":"Thabet","year":"2024","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2025.118264_bib164","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116728","article-title":"Structure-based screening, optimization and biological evaluation of novel chrysin-based derivatives as selective PPAR\u03b3 modulators for the treatment of T2DM and hepatic steatosis","volume":"276","author":"Ma","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118264_bib165","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1002\/jhet.3941","article-title":"PPAR gamma targeted molecular docking and synthesis of some new amide and urea substituted 1, 3, 4\u2010thiadiazole derivative as antidiabetic compound","volume":"57","author":"Vaishnav","year":"2020","journal-title":"J. Heterocycl. Chem."},{"key":"10.1016\/j.ejmech.2025.118264_bib166","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2023.137374","article-title":"Fluorinated thiazole\u2013thiosemicarbazones hybrids as potential PPAR-\u03b3 agonist and \u03b1-amylase, \u03b1-glucosidase antagonists: design, synthesis, in silico ADMET and docking studies and hypoglycemic evaluation","volume":"1301","author":"Fayed","year":"2024","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.ejmech.2025.118264_bib167","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103867","article-title":"Synthesis and evaluation of new 1, 2, 4-oxadiazole based trans-acrylic acid derivatives as potential PPAR-alpha\/gamma dual agonist","volume":"100","author":"Kaur","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118264_bib168","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103115","article-title":"Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of phthalimide-sulfonylurea hybrids as PPAR\u03b3 and SUR agonists","volume":"91","author":"El-Zahabi","year":"2019","journal-title":"Bioorg. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118264_bib169","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1080\/07391102.2020.1714482","article-title":"Virtual screening, molecular dynamics, density functional theory and quantitative structure activity relationship studies to design peroxisome proliferator-activated receptor-\u03b3 agonists as anti-diabetic drugs","volume":"39","author":"Ahmed","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.ejmech.2025.118264_bib170","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2025.142578","article-title":"Design, synthesis and biological evaluation of phenoxyacetic acid derivatives linked to pyrazole scaffold as PPAR-\u03b1\/\u03b3 agonists and COX-2 inhibitors with dual Antidiabetic\/anti-inflammatory activities","author":"Fadaly","year":"2025","journal-title":"J. Mol. Struct."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425010293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425010293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:59:23Z","timestamp":1773190763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425010293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":170,"alternative-id":["S0223523425010293"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118264","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structural and functional insights into PPAR-\u03b3: Review of its potential and drug design innovations for the development of antidiabetic agents","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118264","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118264"}}